According to a recent market study published by Growth Market Reports, titled, “Global Complex Injectable Market is segmented into by type, by application and by region: Size, Share, Trends and Opportunity Analysis, 2017-2032”, the market was valued at US$ 249,067.3 million in 2023 and is expected to grow at a growth rate of 8.5% by the year 2032.

Complex injectables are often used to treat conditions that require precise control over the release of medications. For example, some products are designed to provide a sustained release of medication over several days or weeks, while others are formulated to release medication quickly and rapidly. Additionally, complex injectables are used to deliver medications directly to specific parts of the body, such as the eyes or joints. This targeted delivery helps minimize side effects and improve treatment outcomes.

In terms of packaging and administration, complex injectables come in various forms, including bottles, vials, ampules, and cartridges. Each of these formats has its own advantages and disadvantages, depending on the specific product and patient needs. For example, ampules are used for products that require precise dosing or are sensitive to light and moisture. Cartridges are used for products that require a high level of precision in injection volume or rate. Regardless of the format, complex injectables require careful handling and administration to ensure optimal efficacy and patient safety.

Get Sample Report @ https://growthmarketreports.com/request-sample/547

Based on type, the global complex injectable market is segmented into bottles, vials, ampules, and cartridges. The ampules segment is projected to expand at a significant CAGR during the forecast period, as ampoules are tamper safe as well as offer high chemical resistance and excellent extractable and leachable profiles. Injection ampoules are small and sealed containers typically made of glass that hold a single dose of medication or vaccine in liquid form. They are designed to be opened by breaking off the neck of the ampoule, which is usually scored for easy breaking. This ensures the sterility and integrity of the medication until it is ready to be administered. For instance, according to a data by SCHOTT Pharma, a drug delivery systems manufacturer, glass ampoules held 42% of all commercial injectable solutions stored globally in 2021. It remains one of the popular pharmaceutical containers owing to their many advantages.

On the basis of application, the global complex injectable market is classified into hospitals & clinics, home care settings, ambulatory centers, and others. The hospitals and clinics segment is anticipated to grow at significant CAGR throughout the forecast period, as hospitals and clinics diagnose and treat a wide range of medical conditions, many of which require complex injectables for treatment. This includes conditions such as cancer, autoimmune diseases, chronic illnesses, and rare disorders. For instance, in April 2024, Innocan Pharma begins FDA approval procedure for chronic pain liposome injection therapy. This is expected to increase the demand for complex injectables in hospitals and clinics during the forecast period.

The outbreak of COVID-19 pandemic disrupted the global supply chain, due to lockdown measures, travel restrictions, and manufacturing disruptions. Supply chain issues led to challenges in the production and distribution of several healthcare products, causing delays in delivery and shortages in some regions. Supply chain disruptions moderately impacted the availability of essential raw materials required for manufacturing complex injectable. Governments had imposed social distancing and remote working as well as shut down economic operations globally, which hampered the global complex injectable market.

The pandemic has surged the demand for certain injectable drugs, particularly those used to treat COVID-19 patients, such as antiviral medications, antibiotics, and sedatives for ventilated patients. Moreover, this increased the demand has strained the supply chain and production capacity for these critical injectable drugs, leading to shortages in some cases.

As per growth market reports by industry analyst Raksha Sharma, “Factors such as increasing prevalence of chronic diseases, patient preference for injectable therapies, advancements in biotechnology, and growing demand for self-administration play a significant role in the growth of global complex injectable market.”

Supply chain management is an essential part of any business. Supply chain contains a series of steps to get products from their original state to the customers. These steps include transforming raw materials into final products, transporting those products, and distributing them to the end-users. Quality checks are performed throughout the production process by manufacturers to ensure the quality of the product. The products are then supplied to the distributors. End-users are the final step of the supply chain. End-users of complex injectable include patients with chronic diseases.

Market Key Developments

In October 2023, Pfizer Inc. announced that the US FDA has approved PENBRAYA, the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

The players in the Global Complex Injectable Market include Johnson & Johnson Services, Inc., Pfizer, Inc., Novo Nordisk A/S, Eli Lilly and Company, AbbVie Inc., TEVA PHARMACEUTICAL INDUSTRIES LIMITED, Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, and Others.
 

Report Metric

Details

Market Value in 2023

USD 249,067.3 Million

Market Growth Rate (from 2024 to 2032)

7.06%

Historical Data

2017 & 2022

Base Year

2023

Forecast Period

2024 – 2032

Units Considered

Value (USD Million)

Market Segments

By type, and by application

Key Companies Profiled

Johnson & Johnson Services, Inc., Pfizer, Inc., Novo Nordisk A/S, Eli Lilly and Company, AbbVie Inc., TEVA PHARMACEUTICAL INDUSTRIES LIMITED, Fresenius SE & Co. KGaA, and Hikma Pharmaceuticals PLC.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.


Target Audience:

  • Supply-side: Manufacturer, Suppliers and End-users.

  • Demand Side: Patients with chronic diseases.